Intellia pharmaceuticals stock
NettetIntellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. Our company’s unique strengths … Nettet13. apr. 2024 · Intellia Therapeutics Stock Price Today (NASDAQ: NTLA) Quote, Market Cap, Chart WallStreetZen Intellia Therapeutics Inc Stock Add to Watchlist Overview Forecast Earnings Dividend Ownership $40.55 -0.33 (-0.81%) Updated Mar 16, 2024 1W + 8.36% 1M + 1.81% 3M + 10.01% 1Y - 38.49% NTLA Price $40.55 Fair Value Price …
Intellia pharmaceuticals stock
Did you know?
Nettet24. feb. 2024 · CAMBRIDGE, Mass., Feb. 24, 2024 - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2024. Nettet12. apr. 2024 · Intellia Therapeutics - NTLA Stock Forecast, Price & News $35.96 +0.17 (+0.47%) (As of 04/6/2024 12:00 AM ET) Compare Today's Range $35.13 $36.36 50-Day Range $35.79 $44.82 52-Week Range $32.44 $76.45 Volume 804,840 shs Average Volume 1.13 million shs Market Capitalization $3.17 billion P/E Ratio N/A …
Nettet3. mar. 2024 · Intellia's market valuation has fallen by more than half since it peaked last year, but the company's market cap is still up around $5.9 billion. That's a lot for a … Nettet2. jul. 2024 · Intellia stock has rallied by almost 80% over the last three trading days following the news. Now, we think that this could be a big deal for the broader gene editing sector, as well.
Nettet24. mar. 2024 · Intellia Therapeutics (NASDAQ: NTLA) is a biotechnology company using CRISPR gene-editing technology to develop several experimental drugs, many of with having the potential to save countless lives. As a relatively new drug development technology, Intellia is one of several companies at the forefront of CRISPR-based drug … Nettet21. mar. 2024 · CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) …
NettetIntellia Therapeutics Inc Follow Share $35.96 After Hours: $36.19 (0.64%) +0.23 Closed: Apr 6, 6:28:43 PM GMT-4 · USD · NASDAQ · Disclaimer search Compare to Crispr …
Nettet12 timer siden · Are you looking for some growth stocks than can double in value? Two stocks that analysts appear to be bullish on right now are Intellia Therapeutics (NTLA … dr. neil yager albany medicalNettetfor 1 dag siden · -- Intellia Therapeutics has an average rating of outperform and price targets ranging from $39 to $168, according to analysts polled by Capital IQ. Price: 35.01, Change: +0.43, Percent Change:... April 13, 2024 dr neily venice flNettet27. jan. 2024 · The above is based on 19 Wall Street analysts offering 12-month price targets for Intellia in the last 3 months. The average price target is $173.11 with a high … colette mawdsley hugh bairdNettet1. jun. 2024 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced an expansion of their existing collaboration to provide Regeneron with rights to develop ... colette magny melocoton youtubeNettet13. apr. 2024 · Intellia Therapeutics Stock Performance. Shares of NTLA opened at $34.58 on Thursday. The stock has a fifty day moving average price of $39.20 and a 200 day moving average price of $43.29. colette matthewsNettet13. apr. 2024 · Intellia Therapeutics Stock Performance. 3 Mid-Caps That Could Double in 2024; Shares of NTLA opened at $34.58 on Thursday. The stock has a fifty day moving average price of $39.20 and a 200 day moving average price of $43.29. Intellia Therapeutics, Inc. has a 12 month low of $32.44 and a 12 month high of $76.45. dr neil wright moruyaNettetNTLA Stock Price - Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine ... Pharmaceuticals Major. Employees: 598. Frequently Asked Questions. dr neiman houston